Vutrisiran
Product Specifications
Product Name Alternative
ALN-TTRsc02
UNSPSC Description
Vutrisiran (ALN-TTRsc02) is a liver-directed, investigational, small interfering ribonucleic acid (siRNA) agent. Vutrisiran can be used for transthyretin (TTR)-mediated amyloidosis research[1].
Target Antigen
Small Interfering RNA (siRNA); Transthyretin (TTR)
Type
Oligonucleotides
Related Pathways
Epigenetics;Neuronal Signaling
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/vutrisiran.html
Purity
96.37
Solubility
H2O : ≥ 20 mg/mL
Smiles
[Vutrisiran]
Molecular Weight
16345 (AS: 7556.3; SS: 8788.7 )
References & Citations
[1]Bahru A Habtemariam, et al. Single-Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N-acetylgalactosamine-Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects. Clin Pharmacol Ther. 2021 Feb;109(2):372-382.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-132589/Vutrisiran-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-132589/Vutrisiran-SDS-MedChemExpress.pdf
Clinical Information
Launched
CAS Number
1867157-35-4
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6295257-01 0.1 mL
ELL, CT (ELL, C19orf17, RNA polymerase II elongation factor ELL, Eleven-nineteen lysine-rich leukemia protein) (MaxLight 750)
Ask
View Details MBS6295257-02 5x 0.1 mL
ELL, CT (ELL, C19orf17, RNA polymerase II elongation factor ELL, Eleven-nineteen lysine-rich leukemia protein) (MaxLight 750)
Ask
View Details 